Impact of Genetic Polymorphisms on Insulin Resistance by Komurcu-Bayrak, Evrim
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books










© 2012 Komurcu-Bayrak, licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Impact of Genetic Polymorphisms  
on Insulin Resistance 
Evrim Komurcu-Bayrak 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/51595 
1. Introduction 
The identification of DNA polymorphisms in human populations is an important step 
towards understanding the contribution of functional genetic variants to predisposition of 
diseases or clinical phenotypes. Approach to the determination of the predisposition uses 
polymorphisms as marker for a disease in an affected DNA population compared to a 
control DNA population. Subsequently, the polymorphisms statistically associated with the 
disease group may be directly informative or linked to the probable causative variant. There 
are currently over 10 million single nucleotide polymorphisms (SNPs) including 
insertion/deletion variants in public databases that potentially provide a marker set for 
disease-gene association studies. This large variant set might not represent the variants 
causative of disease because it was performed in genomes of only a limited number of 
individuals. For this reason, the discovery genetic variation in regions of functional DNA 
sequence in the genomes of individuals with disease is important for disease-gene 
association studies. However, this situation is not practicable for complex polygenic disease. 
Therefore, recently, genome-wide association (GWA) or candidate gene approaches are used 
in the understanding of the molecular genetic background of complex polygenic disease.  
Insulin resistance has a complex and heterogeneous genetic background. Insulin resistance 
is caused by the reduced ability of peripheral target tissues to respond properly to insulin 
stimulation. Insulin resistance predates beta cell dysfunction and plays the crucial role in the 
pathogenesis of type 2 diabetes. In addition, insulin resistance is considered the core factor 
in the pathogenesis of atherosclerosis and the metabolic syndrome, and is often associated 
with obesity, hypertension and also a dyslipidemic profile characterized by high plasma 
triacylglycerol concentrations and low HDL-C (Reaven, 1988; Filippi et al., 2004). Until now, 
many hypotheses have been proposed to explain the molecular mechanisms of insulin 
resistance such as insulin signaling cascade, the role of free fatty acids, adipocytokines, and 
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inflammation (Perseghin et al., 2003; Bhattacharya et al. 2007; Choi & Kim, 2010; Erion & 
Shulman, 2010; Muoio &, Newgard, 2008). Given the crucial roles of pathways in the 
pathogenesis of liver and muscle insulin resistance, understanding the molecular 
mechanism of insulin resistance is vital for the development of new and more effective 
therapies for metabolic disorders. The homeostasis model assessment (HOMA) index for 
insulin resistance was calculated as the product of fasting plasma insulin (in microunits per 
milliliter) and fasting plasma glucose (in millimoles per liter), divided by 22.5 (Matthews et 
al. 1985). Higher HOMA values indicate higher insulin resistance.  
Genetic and epidemiological studies strongly suggest that insulin resistance is, at least in 
part, genetically determined. However, the involved genes and their effective variants are 
mostly unknown. The numerous genes have been suggested as a potential candidate gene 
for insulin resistance, but the findings of these studies were controversial. This chapter is to 
provide an overview of our recent understanding of genetic predisposition to insulin 
resistance. It is aimed to summarize the results of the recent studies about the genetics of 
insulin resistance.  
2. Genes related to the lipid homeostasis 
2.1. The polymorphisms of the FABP genes  
Fatty acid-binding proteins (FABPs) are members of a superfamily of lipid-binding proteins. 
These tissue specific proteins (FABP1-4) play the physiological role in the uptake, 
intracellular metabolism and excretion of long-chain fatty acids (LCFA) (Zimmerman & 
Veerkamp, 2002). The polymorphisms of these genes have been studied in several metabolic 
phenotypes such as obesity, metabolic syndrome, hypertriglyceridemia and insulin 
sensitivity (Mansego et al. 2012). 
The liver FABP (FABP1) is an abundant cytosolic lipid-binding protein that regulates lipid 
transport and metabolism. The c.334-135G>A polymorphism (rs2197076) located in the 3 
prime untranslated region (UTR) of the FABP1 gene was associated with the risk of type 2 
diabetes and HOMA index in the Spanish population. In this study, it has been shown that 
carriers of the allele A of this polymophism had HOMA index values higher than 
homozygotes GG. However, none of the other analyzed variants in FABP2, FABP3 and 
FABP4 genes were associated with type 2 diabetes and insulin resistance in this study 
(Mansego et al. 2012). 
The intestinal FABP (FABP2) plays a key role in the absorption and intracellular transport of 
dietary LCFA (Weiss, 2002). Therefore, the FABP2 gene has been suggested as a possible 
candidate gene for type 2 diabetes and insulin resistance. In vitro experiments have shown 
that Ala54Thr polymorphism increases the affinity of FABP2 for LCFA and is associated 
with increased triglyceride transport in human intestinal cells (Baier et al., 1996; Prochazka 
et al., 1993). Previous studies have reported significant associations between the FABP2 gene 
and increased prevalence of insulin resistance (Baier et al., 1995; Mitchell et al., 1995; 
Yamada et al. 1997; Chiu et al., 2001; Kim et al., 2001) as well as no association was found in 
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Finnish individuals (Sipiläinen et al., 1997) and Spanish population (Mansego et al. 2012). 
Baier et al. reported the significant associations between the common FABP2 Ala54Thr 
polymorphism (rs1799883) and increased fasting insulin concentration, fasting fatty acid 
oxidation, and decreased insulin sensitivity in Pima Indians, a population with a high 
prevalence of obesity and type 2 diabetes (Baier et al., 1995). Furthermore, the linkage 
analysis of the FABP2 locus with insulin resistance was also found in a study in Mexican 
Americans who were of a mixed American-Indian and -European ancestry (Mitchell et al., 
1995). However, sib-pair analysis failed to detect any linkage of the FABP2 locus or the 
Ala54Thr polymorphism with diabetes-related phenotypes in other ethnic groups. The 
homozygous Thr54/Thr54 genotype has found the associations with higher fasting insulin 
levels and also TNF-α levels in 33 adult obese women (Albala et al., 2004). However, the 
findings of this study would need to be confirmed in studies involving a larger number of 
subjects. A number of conflicting and inconclusive studies have investigated the possible 
association of the FABP2 Ala54Thr polymorphism with insulin resistance. A meta-analysis 
of these published studies has suggested that the Thr54 allele of the FABP2 Ala54Thr is 
weakly associated with a higher degree of insulin resistance, higher fasting insulin and 
blood glucose level. As gender and ethnicity probably were important variables in 
determining associative risk with insulin resistance and type 2 diabetes, Zhao et al. have 
performed subgroup analyses of gender and ethnicity. These weak effects of Ala54Thr 
polymorphism on insulin resistance and fasting insulin have been particularly established in 
East Asians (Zhao et al., 2010). 
2.2. The polymorphisms of the ELOVL6 gene 
Elongase of long chain fatty acids family 6 (ELOVL6) is expressed in lipogenic tissues. This 
enzyme specifically catalyze the elongation of saturated and monounsaturated fatty acids 
with 12, 14 and 16 carbons. A population-based study has suggested that the genetic 
variations in the ELOVL6 gene are related with insulin resistance. In this study, five SNPs of 
the ELOVL6 gene and their haplotypes were analyzed. In this population from southern 
Spain, carriers of the minor alleles of the rs9997926 and rs6824447 polymorphisms had a 
lower risk of having high HOMA index, whereas carriers of the minor allele rs17041272 had 
a higher risk of being insulin resistant. Finally, Morcillo et al. has suggested that the 
ELOVL6 gene could be a future therapeutic target in the treatment of diabetes and related 
disorders (Morcillo et al., 2011). However, the validation of associations between this novel 
candidate gene and insulin resistance should be performed in different and large 
populations. 
2.3. The polymorphisms of the APOE gene 
Apolipoprotein E (ApoE) is primarily involved in plasma lipid homeostasis. However, a 
number of studies with experimental mouse models have shown that apoE also has an 
important role in the development of obesity and insulin resistance (Kypreos et al., 2009; 
Gao et al., 2007). ApoE is involved in excess fat accumulation and energy metabolism, 
including the regulation of food intake and energy expenditure. Therefore, excess fat 
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accumulation via an apoE-dependent pathway might play a role in the development of 
insulin resistance (Kypreos et al., 2006). Some studies have suggested that the APOE 
ε2/ε3/ε4 polymorphism may modify the effect of insulin on CHD or some CHD risk factors, 
including obesity and lipid profile levels (Després et al., 1993; Valdez et al., 1995; Elosua et 
al., 2003), whereas the Framingham Offspring Study and Turkish Adult Risk Factor (TARF) 
Study found that this polymorphism was not associated with insulin resistance (Meigs et al., 
2000; Komurcu-Bayrak et al., 2011). Two other of the functional SNPs, i.e., -219G>T 
(rs405509) and +113G>C (rs440446) in APOE gene had shown association with plasma apoE 
concentrations (Lambert et al., 2000; Moreno et al., 2003), insulin resistance (Viitanen et al., 
2001), insulin sensitivity in response to a diet rich in satured fats (Moreno et al., 2005). In a 
cross-sectional study, the impacts of these polymorphisms have been analyzed on lipid, 
apolipoprotein, glucose, and serum insulin concentrations in the TARF cohort, a 
representative of Turkish adults. In this study, the -219G>T and +113G>C genotypes and 
diplotypes of haplotype 2 (TCε3) showed negative correlation to serum fasting insulin and 
the HOMA index, but not to serum lipids. The significant associations between these 
functional polymorphisms and fasting insulin levels and the HOMA index were found only 
in the apoE3 group (ε3ε3 genotypes of the APOE ε2/ε3/ε4 polymorphism) without type 2 
diabetes (Komurcu-Bayrak et al., 2011). On the other hand, a large population-based family 
study related with type 2 diabetes found a relationship for the polymorphisms of the APOE 
gene and the nearby muscle glycogen synthase (GYS1) gene on chromosome 19 with 
cardiovascular mortality, independently of each other (Fredriksson et al., 2007). Other 
functional polymorphisms in the GYS1 gene may relate to developing insulin resistance.  
3. Genes related to the energy metabolism 
3.1. The polymorphisms of the UCP genes 
Uncoupling protein 2 and 3 (UCP2 and UCP3) play an important role in human energy 
homeostasis (Brand et al., 200 4) and have been considered candidate genes for obesity, type 
2 diabetes and insulin resistance. Thus, UCP2 and UCP3 are involved in regulating ATP 
synthesis, generation of reactive oxygen species and glucose-stimulated insulin secretion by 
pancreatic β cells. The -866G>A (rs659366) polymorphism of UCP2 gene was located in a 
region with putative binding sites for two β-cell transcription factors (Dalgaard et al., 2003). 
A number of studies have been performed seeking for an association between genetic 
variants in this gene cluster with type 2 diabetes and/or insulin resistance. These studies 
have demonstrated association of the -866A-allele with increased (D’Adamo et al., 2004; 
Krempler et al., 2002; Gable et al., 2006) and decreased (Wang et al., 2004; Bulotta et al., 2005; 
Lyssenko et al., 2005; Rai et al., 2007) risk of type 2 diabetes as well as no association at all 
(Kovacs et al., 2005; Reis et al., 2004; Zee et al., 2011). Finally, the two recent meta-analysis 
on the association of type 2 diabetes with -866G>A polymorphism concluded that this 
variant does not confer increased risk of type 2 diabetes (Xu et al., 2011; 40, Andersen et al., 
2012). However, Andersen et al has found an association between this variant and obesity in 
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Danish individuals and established case-control studies. This study has shown that the -
866G-allele was associated with elevated fasting serum insulin levels and insulin resistance 
(HOMA index) and decreased insulin sensitivity in Danish subjects (Andersen et al., 2012). 
Furthermore, in a study performed with a Spanish group of 193 obese children and 
adolescents and 170 controls, Ochoa et al. reported that the -55C>T (rs1800849) 
polymorphism of the UCP3 gene directly associated with higher fasting insulin levels and 
insulin resistance in heterozygous subjects from the control group. In addition, they found 
that the individual polymorphisms were not associated with obesity, but the (-866G) - (Del; 
45 bp) - (-55T) haplotype was significantly associated with obesity and its presence in the 
control group increased about nine times the insulin resistance risk (Ochoa et al., 2007). 
Recently, a study has demonstrated that morbidly obese patients with –55CT genotype 
(n=15) had higher weight, fat mass, and insulin resistance (HOMA index) than the 
individuals with −55CC genotype (n=32) (de Luis Roman et al., 2010). 
3.2. The polymorphisms of the ADRB genes 
β-adrenoceptors (ADRB1, ADRB2, ADRB3) in the sympathetic nervous system play a role in 
regulating energy expenditure and lipolysis. ADRBs gene variation is an intense area of 
investigation because β-adrenoceptors are well described in organ system distribution, 
catecholamine-mediated physiological processes, disease states and treatment targets 
(Eisenach & Wittwer, 2010). One of the most studied polymorphism (rs1801253) in the 
ADRB1 gene encode for arginine or glycine in amino acid 389 (Arg389Gly).  In 238 healthy 
young Caucasians and African-Americans, Gly389 carriers had a higher level of insulin and 
insulin resistance than non-carriers, and this allele was more prevalent in the subjects with 
higher body mass index (BMI; Lima et al. 2007). In previous studies, it has been found that 
this polymorphism was associated with serum insulin levels and insulin resistance (HOMA 
index) but, no association with obesity among Swedish women (Mottagui-Tabar et al., 2008). 
However, there are limited number of studies evaluating the association between these 
genes and insulin resistance. In larger scale studies with different populations should be 
performed for these genes to support the association between genotype and phenotype. 
4. Genes encoding hormones and hormone receptors  
4.1. The polymorphisms of the APM1, ADIPOR1, and ADIPOR2 genes 
Adiponection is an adipokine secreted by adipocytes. The polymorphisms in adiponectin 
(APM1,ADIPOQ, ACRP30) gene, and its receptors (ADIPOR1 and ADIPOR2) are strongly 
associated with metabolic syndrome, obesity, type 2 diabetes and, insulin resistance. High 
adiponectin predicts increased insulin sensitivity (Tschritter et al. 2003). There is evidence 
indicating that insulin directly affects plasma adiponectin (Möhlig et al., 2002; Hung et al., 
2008; Brame et al., 2005). In recent studies, plasma adiponectin concentrations were 
reduced in type 2 diabetes and obesity (Arita et al., 1999; Lindsay et al. 2002; Spranger et 
al., 2003). Furthermore, administration of thiazolidinediones (TZD), an insulin-sensitising 
class of drugs, to insulin-resistant subjects significantly increased the plasma adiponectin 
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levels, and this effect was correlated with the amelioration of insulin resistance in these 
subjects (Maeda et al., 2001). Many studies have, in fact, reported the association between 
polymorphisms of the APM1, ADIPOR1, and ADIPOR2 and adiponectin concentrations, 
insulin resistance, type 2 diabetes and metabolic syndrome phenotypes (Kondo et al., 
2002; Hara et al., 2002; Menzaghi et al., 2002; Stumvoll et al., 2002; Hivert et al., 2008; 
Menzaghi et al.,2007; Sheng et al., 2008; Ferguson et al., 2010). While, in the study from 
Stumvoll et al, the +45T>G (rs2241766) polymorphism was associated with obesity and 
derangement of insulin sensitivity (Stumvoll et al., 2002), in the study from Melistas et al, 
this polymorphism was associated with lower insulin levels in Greek women without 
diabetes (Melistas et al., 2009). In a study from Menzaghi et al, a haplotype of the 
adiponectin gene was associated with several features of insulin resistance in nondiabetic 
individuals, including low serum adiponectin levels (Menzaghi et al., 2002). In addition, 
the +276G>T (rs1501299) polymorphism in the adiponectin gene was associated with 
higher insulin levels and insulin resistance (HOMA index) in Italian population from the 
Lazio region (diabetes and/or the metabolic syndrome was excluded) (Filippi et al., 2004) 
and in Greek female population without diabetes (Melistas et al., 2009). The association of 
the -11391G>A (rs17300539) polymorphism with plasma insulin and HOMA index was 
independent of plasma adiponectin in another study, which implies a direct effect of this 
polymorphism on plasma insulin and insulin sensitivity (Henneman et al., 2010).  
Recently, Vasseur et al have reported on the association of a haplotype G-G (including -
11391G>A and -11377C>G polymorphisms located in the APM1 proximal promoter) with 
plasma adiponectin levels and type 2 diabetes, although no association with HOMA index 
was observed (Vasseur et al., 2002). The reasons for partially discrepant results between 
polymorphisms in these genes and metabolic measures could be due to the different 
genetic background of the studied populations or environmental interactions, particularly 
dietary factors. Gene-nutrient interactions can modulate in the development of metabolic 
phenotypes. Although, so far, there has been little focus on gene-nutrient interactions 
with adiponectin and its receptors, two studies found that there was an interaction 
between the rs266729 polymorphism of APM1 and the percentage of dietary-derived 
energy from fat with the development of obesity in women (Santos et al., 2006) and an 
association between this polymorphism and also the rs10920533 polymorphism of 
ADIPOR1 and plasma saturated fatty acids with the insulin resistance (Ferguson et al., 
2010). 
4.2. The polymorphisms of the D2 and TSHR genes 
Thyroid hormones are known to upregulate the expression of glucose transporter type 4 
(GLUT4) in skeletal muscle, and consequently increase glucose uptake (Weinstein et al., 
1994). Thyroxine (T4), a major secretory product of the thyroid gland, needs to be 
converted to triiodothyronine (T3) to exert its biological activity. Type 2 deiodinase (D2) 
catalyzes T4 to T3 conversion, and plays a critical role in maintaining intracellular T3 
levels in specialized tissues, such as the anterior pituitary and brown adipose tissue 
(Bianco et al., 2005). Thr92Ala polymorphism of D2 gene showed an association with 
lower glucose disposal rate in nondiabetic subjects and also a higher prevalence of insulin 
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resistance in Pima Indians and Mexican–Americans (Mentuccia et al., 2002). Furthermore, 
D2 Ala/Ala genotype was also associated in previous studies with increased insulin levels 
and increased insulin resistance (increased HOMA index) and also worse glycemic control 
(increased HbA1c levels) in a cohort of patients with type 2 diabetes (Grozovsky et al., 
2009; Dora et al., 2010). In addition, this polymorphism was associated with greater 
insulin resistance in type 2 diabetes patients and with lower enzyme activity in thyroid 
tissue samples (Canani et al., 2005). However, some population-based studies failed to 
demonstrate an association between the D2 Thr92Ala polymorphism and increased risk 
for type 2 diabetes (Mentuccia et al., 2005; Maia et al., 2007; Grarup et al. 2007). Thyroid 
hormone interacts with the TSH receptor (TSHR) in the thyroid gland. A previous study 
has investigated the association between serum thyroid parameters and the TSHR 
Asp727Glu polymorphism in nondiabetic elderly men. Peeters et al. reported that this 
polymorphism was associated with relative insulin resistance. Carriers of the Glu727 
allele had also a significantly higher glucose, insulin, HOMA index and leptin levels, but 
no association with serum TSH levels (Peeters et al., 2007). Peeters et al. have suggested 
that this association was studied in one cohort only, and as the mechanism remains to be 
elucidated, replication of results in an independent cohort (of healthy elderly subjects) 
was essential. 
4.3. The polymorphisms of the SHBG gene 
Some studies have suggested that the polymorphisms in genes encoding sex hormones may 
be effective on the development of insulin resistance. Previous studies have shown that 
androgen supplementation in the presence of central obesity and low testosterone levels 
increases insulin sensitivity in men (Mårin et al., 1992; Simon et al., 2001; Boyanov et al., 
2003). Moreover, polycystic ovarian syndrome was associated with higher risk of type 2 
diabetes and insulin resistance in women (Dunaif, 1995). Recent studies have demonstrated 
that higher levels of circulating sex hormone binding protein (SHBG) were associated with 
reduce risk of type 2 diabetes (Ding et al., 2009; Perry et al., 2010). In addition, rs6259, rs6257 
and rs1799941 polymorphisms in the SHBG gene were strongly associated with SHBG levels 
and type 2 diabetes (Zeggini et al., 2008; Perry et al., 2010). However, there was no evidence 
that this variant is associated with diabetes-related intermediate traits, including several 
measures of insulin secretion and resistance (Perry et al., 2010). 
4.4. The polymorphisms of the LEP and LEPR genes 
Leptin (LEP), a hormone secreted by adipocytes, and its receptor (LEPR) are other candidate 
genes for insulin resistance.  Common variants in the LEPR gene have been associated with 
hyperinsulinemia (Lakka et al., 2000; Wauters et al., 2002), type 2 diabetes (Lakka et al., 
2000), obesity, and leptin levels (Chagnon et al., 1999; Chagnon et al., 2000; Chagnon et al., 
2001; de Luis Roman et al., 2006). However, the roles of leptin and its receptor in the 
development of metabolic traits in the general population are less clear. A few studies have, 
in fact, reported the association between polymorphisms of the LEP and LEPR genes and 
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insulin resistance (Wauters et al., 2001; de Luis et al., 2008; Gu et al., 2012; Takahashi-Yasuno 
et al., 2004; Ren et al., 2004). While, in the study from Wauters et al, Lys109Arg, Gln223Arg, 
and Lys656Asn polymorphisms in LEPR gene were associated with insulin and glucose 
metabolism in postmenopausal obese women with impaired glucose homeostasis (Wauters 
et al., 2001), in the study from de Luis et al, Lys656Asn polymorphism was associated with 
higher levels of insulin, HOMA, and leptin in men without diabetes (de Luis et al., 2008) , in 
the study from Gu et al, Lys109Arg was associated with waist-to-hip ratio, oral glucose 
tolerance test (OGTT)-2h glucose, and HOMA index in Chinese subjects with essential 
hypertension, but no correlation between Lys109Arg polymorphism and hypertension were 
found (Gu et al., 2012). Also’ -2549C>A polymorphism in the promoter region of the LEP 
gene is related to fasting plasma leptin level (Mammès et al., 1998; Le Stunff et al., 2000; Gu 
et al., 2012), obesity phenotypes (Mammès et al., 1998; Mammès et al., 2000; Le Stunff et al., 
2000), and also fasting serum insulin level and HOMA index in Chinese patient with type 2 
diabetes (Ren et al., 2004).  However, the findings of the study from Ren et al. should be 
confirmed with studies involving larger number of subjects and different populations. 
4.5. The polymorphisms of the RBP4 gene 
Retinol-binding protein 4 (RBP4) is an adipokine with potential contribution to systemic 
insulin resistance (Yang et al., 2005).  The -803G>A promoter polymorphism (rs3758539) of 
RBP4 gene is associated with increased risk for obesity and type 2 diabetes in adults 
(Munkhtulga et al., 2010 ; Munkhtulga et al., 2007; van Hoek et al., 2008). Munkhtulga et al. 
have reported in 2010 that the -803A allele of this polymorphism was associated with higher 
BMI in Japanese men and women and in Mongolian women (Munkhtulga et al., 2010) and 
also in 2007 they found that the rare alleles of four SNPs (-803G>A, +5169C>T, +6969G>C, 
+7542T>del) were associated with increased risk of diabetes in Mongolian case-control study 
(Munkhtulga et al., 2007). van Hoek et al. have shown that homozygosity for the −803A 
allele was associated with increased risk of type 2 diabetes in the Rotterdam population (van 
Hoek et al., 2008). More recent studies failed to confirm an association of this variant with 
circulating RBP4 levels, type 2 diabetes susceptibility, adiposity or metabolic parameters 
(Friebe et al., 2011; Kovacs et al., 2007; Shea et al., 2010; Wu et al., 2009; Craig et al., 2007). 
Shea et al. have analyzed five SNPs including -803G>A polymorphism within RBP4 gene 
and they have found a significant association between the minor allele of rs10882280 (C>A 
intron) and rs11187545 (A>G intron) polymorphisms and higher serum HDL-C levels in 
Newfoundland population, but not between insulin resistance and any polymorphism (Shea 
et al., 2010). Craig et al. have found that only a haplotype (-804G, 390G, 406T, 759G, 6969G, 
9476T, 10670G, and 11881C) in RBP4 gene showed an association with type 2 diabetes in 
African Americans and Caucasians. Furthermore, -803G>A and +9476T>G (rs34571439) 
polymorphisms were associated with reduced insulin secretion, and +390C>G (novel) with 
reduced insulin sensitivity in Caucasians (Craig et al., 2007). The discrepancy among 
previous publications about insulin resistance may be resolved by analyzing a larger 
number of samples. 
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4.6. The polymorphisms of the RETN gene 
Resistin (RETN), a hormone secreted by adipocytes, has been examined as candidate gene 
for obesity and type 2 diabetes and insulin resistance.  However, there are many conflicting 
findings about these metabolic phenotypes. Osawa et al. have reported that the GG 
genotype of RETN -420C>G promoter polymorphism (rs1862513), increased type 2 diabetes 
susceptibility (Osawa et al., 2004) and fasting plasma resistin (Osawa et al., 2007; Azuma et 
al., 2004) in the Japanese population. Silha et al. and Osawa et al. have found correlation 
between resistin levels and insulin resistance (Silha et al.,2003; Osawa et al., 2007), but not 
Lee et al. (Lee et al., 2003). Some genetic association studies have found an association 
between certain resistin gene variants and insulin resistance in Finnish nondiabetic 
individuals (Conneely et al., 2004), in nondiabetic Caucasians from Sicily and Gargano areas 
of Italy (Pizzuti et al., 2002), and in 20 nondiabetic Caucasians (Wang et al., 2002), while 
others report no such association in 60 Japanese obese nondiabetic individuals (Azuma et 
al., 2004) and  in 258 families with 323 affected with polycystic ovary syndrome offspring 
(Urbanek et al., 2003). These conflicting findings have made it difficult to determine a role 
for resistin in insulin resistance. The reasons for discrepant results are not known, and may 
reside in the different genetic background of the studied populations or the different-
designed studies. 
5. Genes related to the renin-angiotensin system 
The renin-angiotensin system (RAS) plays a central role in the regulation of insulin 
sensitivity (Reaven, 1995; Higashiura et al., 2000; Ura et al., 1999). Many studies have 
examined the genetic effect of homozygous deletion polymorphism (DD) in exon 16 of the 
angiotensin-converting enzyme gene (ACE) in insulin resistance, but their results have been 
controversial (Katsuya et al., 1995; Perticone et al., 2001; Yamamoto et al., 1999). 
Hypertension is related to insulin resistance and a number of studies have reported an 
association between RAS gene polymorphisms and hypertension (Sugimoto et al. 2004; Jin et 
al., 2003; Kikuya et al., 2003; Ono et al., 2003). Akasaka et al., 2006; The insertion/deletion 
(I/D) polymorphism of the angiotensin-converting enzyme gene (ACE), the Met235Thr 
polymorphism of the angiotensinogen gene (AGT), and the 1166A>C polymorphism of the 
angiotensin II type 1 receptor gene (AGTR1) were not associated with HOMA index, 
whereas borderline association was found between the 1166A>C polymorphism and 
dichotomous categorization of insulin resistance (defined as HOMA index ≥1.73). However, 
further studies are required to confirm the impact of these candidate gene polymorphisms 
in the larger and different populations. 
6. Genes related to the inflammation  
6.1. The polymorphisms of the TNF-α gene  
Tumor necrosis factor alpha (TNF-α) is a multifunctional proinflammatory cytokine and 
also an adipokine produced in adipocytes. Increased levels of the TNF-α have been shown 
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to elevate the risk of insulin resistance by impairing β cell function and glucose homeostasis 
(Hotamisligil et al., 1993; Hotamisligil et al., 1994; Katsuki et al., 1998). In addition, the TNF-
α affects lipid metabolism and may lead to hypertriglyceridemia by decreasing hepatic 
lipoprotein lipase activity and by increasing hepatic de novo fatty acid synthesis (Zinman et 
al., 1999). Circulating levels of TNF-α have also been reported to correlate with insulin 
resistance and type 2 diabetes (Hotamisligil & Spiegelman, 1994; Hu et al., 2004). Previous 
studies have shown that TNF-α -308G>A polymorphism is associated with insulin resistance 
(Fernandez-Real et al., 1997), obesity (Hoffstedt et al., 2000), type 2 diabetes (Vendrell et al., 
2003; Kubaszek et al., 2003) and metabolic syndrome (Gupta et al., 2012). However, many 
other studies have reported conflicting results, with no association between this variant and 
insulin resistance (Gupta et al., 2012; Ranjith et al., 2008). A meta-analysis of many published 
studies including different populations has suggested that -308A TNF-α gene variant is 
associated with increased risk of developing obesity compared with controls and 
significantly higher systolic arterial blood pressure and plasma insulin levels (Sookoian et 
al., 2005). On the other hand, another recent meta-analyses has reported that TNF-α -
238G>A and -308G>A polymorphisms were not associated with type 2 diabetes mellitus; 
however, -308G>A polymorphism was positively associated with type 1 diabetes (Feng et 
al., 2009a; Feng et al., 2009b; Feng et al., 2011). TNF-α -857C>T polymorphism is also 
associated with obese type 2 diabetes (Kamizono et al. 2000) and insulin resistance in 
Japanese diabetic subjects with adiponectin +276GG genotype (Ohara et al., 2012). The study 
of Ohara et al has shown interaction of TNF-α and adiponectin genes with insulin resistance 
and fatty liver (Ohara et al., 2012). 
6.2. The polymorphisms of the IL-6 gene 
Interleukin-6 (IL-6) is a proinflammatory cytokine that is associated with type 2 diabetes and 
insulin resistance (Di Renzo et al., 2008; Wannamethee et al., 2007; Hu et al., 2004). Recent 
studies has demonstrated that the association between -174G>C polymorphism (rs1800795) 
in the promoter region of the IL-6 gene and insulin resistance is modified by body mass 
index (BMI), with the -174C allele associated with higher insulin resistance and type 2 
diabetes in individuals with obesity (Herbert et al., 2006; Mohlig et al., 2004; Goyenechea et 
al., 2007; Di Renzo et al., 2008; Underwood et al., 2012). However, in meta-analysis including 
5383 diabetes cases and 12 069 controls, it has been found that -174G>C polymorphism was 
not associated with the risk of type 2 diabetes (Qi et al., 2006). The reasons underlying the 
discrepancy among studies are unclear. Other genetic or environmental factors may play 
important roles in modulating the relationships. 
7. Conclusion 
The insulin resistance is highly heritable and originates from the interactions of multiple 
genes and environmental factors. Figure 1 shows the main factors contributing to the 
development of insulin resistance and type 2 diabetes. However, the molecular mechanism 
of insulin resistance is not clear yet. Until now, goal of many studies was to use a candidate 
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gene approach to identify genes associated with insulin resistance and several genes have 
been investigated in many association-based studies. However, most of the time, results of 
these studies reveal conflicting findings. These discrepant results might be due to 
differences in the study populations and design of these studies. In addition, the candidate 
gene polymorphisms have been searched in a number of small-scale studies with variable 
results. Limited number meta-analyses have been done to demonstrate the effect of several 
candidate gene polymorphisms on insulin resistance. But, the larger, well-characterized and 
independent association studies will be needed. On the other hand, the use of genome-wide 
association (GWA) studies will identify novel polymorphisms related to insulin resistance. 
This knowledge will allow the determination of the genetic predisposition to the insulin 
resistance and new approaches to treatment and prevention of the clinical phenotypes such 
as type 2 diabetes, obesity, hypertension and metabolic syndrome. 
 
Figure 1. General overview of genetic and environmental factors contributing to the development of 
insulin resistance and type 2 diabetes. The combination of genetic predisposition (genetic 
polymorphisms effecting free fatty acid metabolism, insulin signalling, adipokines and cytokines) and 
some environmental factors such as excessive dietary intake and physical inactivity results with the 
occurrence of adipocytogenesis, lipodystrophy and obesity which increase the development risk of 
insulin resistance. Insulin resistance predates pancreatic beta cell dysfunction and plays the crucial role 
in the pathogenesis of type 2 diabetes. 
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